SLC5A2 and type 2 diabetes mellitus: Therefore, in this study, we used metformin as a positive control in our animal experiments and compared its effect to dapagliflozin, an SGLT2 inhibitor. We found that treatment with dapagliflozin could alleviate left ventricular remodelling (Figure 1A,B) as well as improve both diastolic and systolic cardiac function (Figure 1C,D), in rats with type 2 diabetes.